[1]吴海艳,王旭.芪苓肾消汤治疗气阴两虚夹瘀型糖尿病肾病40例临床观察[J].甘肃中医药大学学报,2017,34(06):48-52.[doi:10.16841/j.issn1003-8450.2017.06.14]
 WU Haiyan,WANG Xu.Clinical study on 40 cases of diabetic kidney disease that deficiency of both qi and yin with blood stasis treated with Qiling Shenxiao Tang[J].Journal of Gansu University of Chinese Medicine,2017,34(06):48-52.[doi:10.16841/j.issn1003-8450.2017.06.14]
点击复制

芪苓肾消汤治疗气阴两虚夹瘀型糖尿病肾病40例临床观察()
分享到:

《甘肃中医药大学学报》[ISSN:1003-8450/CN:62-1062/R]

卷:
34卷
期数:
2017年06期
页码:
48-52
栏目:
临床研究与报道
出版日期:
2017-12-25

文章信息/Info

Title:
Clinical study on 40 cases of diabetic kidney disease that deficiency of both qi and yin with blood stasis treated with Qiling Shenxiao Tang
作者:
吴海艳1 王旭2
1. 昆山市中医院(南京中医药大学附属医院)内分泌科, 江苏 昆山 215300;
2. 南京中医药大学第一临床医学院, 江苏 南京 210029
Author(s):
WU Haiyan1 WANG Xu2
1. Endocrinology Department, Kunshan TCM Hospital, Kunshan, Jiangsu, 215300, China;
2. First Clinical Medicine College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210029, China
关键词:
糖尿病肾病气阴两虚夹瘀型芪苓肾消汤缬沙坦胶囊临床观察
Keywords:
diabetic kidney diseasedeficiency of both qi and yin with blood stasisQiling Shenxiao TangValsartan capsulesclinical observation
分类号:
R256.5
DOI:
10.16841/j.issn1003-8450.2017.06.14
摘要:
目的 观察芪苓肾消汤治疗气阴两虚夹瘀型糖尿病肾病(DKD)的临床疗效。方法 将79例DKD患者随机分为2组。对照组39例在常规西医治疗的基础上给予缬沙坦胶囊口服,治疗组40例在对照组治疗方法的基础上加用芪苓肾消汤治疗。治疗8周后评定疗效,并比较2组的中医证候积分,尿微量白蛋白(MAU)、24小时尿蛋白定量、尿素氮(BUN)、血肌酐(Scr)、内生肌酐清除率(Ccr)、空腹血糖(FBG)及糖化血红蛋白(HbA1c)含量,不良反应发生情况。结果 对照组总有效率为66.7%,治疗组为90.0%,2组比较差异有统计学意义(P<0.05)。2组治疗后中医证候积分均显著降低,与同组治疗前比较,差异有统计学意义(P<0.05),且治疗组降低更显著(P<0.05)。2组治疗后MAU、24小时尿蛋白定量及BUN显著降低,Ccr显著升高,与同组治疗前比较,差异均有统计学意义(P<0.05);治疗组治疗后Scr显著降低,与同组治疗前比较,差异有统计学意义(P<0.05);治疗组对各项指标的改善程度明显优于对照组(P<0.05)。2组治疗前后FBG,HbAlc比较,差异均无统计学意义(P>0.05)。结论 芪苓肾消汤可有效改善气阴两虚夹瘀型DKD患者的临床症状及肾功能指标,方法可行,疗效可靠,值得临床推广应用。
Abstract:
Objective To investigate the curative effect of Qiling Shenxiao Tang in treating diabetic kidney disease(DKD) that deficiency of both qi and yin with blood stasis. Methods 79 DKD patients were randomly divided into treatment group (40 cases) and control group (39 cases). The control group took Valsartan capsules orally on the basis of conventional western medicine while the treatment group was treated with Qiling Shenxiao Tang addtionally besides Valsartan capsules.After 8 weeks,the curative effect,syndrome integrals,microalbuminuria (MAU),24 h quantitation of urine protein (UP),blood urea nitrogen(BUN),endogenous creatinine clearance rate (Ccr) and serum creatinine (Scr),fasting blood glucose (FBG),glycated hemoglobin (HbAlc) and adverse effect were detected and analyzed statistically. Results The total effective rate in control group was 66.7% while that in treatment group was 90.0%,the difference was statistically significant (P<0.05). Syndrome integrals of two groups decreased evidently after treatment while that of treatment group changed more,the differences were all significant (P<0.05). Indexes of MAU,UP (24 h) and BUN decreased while that of Ccr increased in both groups after treatment,there were significant differences (P<0.05). Scr decreased in treatment group more than before while improvement in it was better than that in control group (P<0.05). There were no significant differences in FBG and HbAlc after treatment (P>0.05). Conclusion Qiling Shenxiao Tang is effective in relievig syndrome of DKD that deficiency of both qi and yin with blood stasis and improving renal function. The therapy is feasible and realiable,worth popularizing and applying in clinic.

参考文献/References:

[1] 邹万忠,陈楠,胡仁明.糖尿病肾脏病变的诊断[J].中国处方药,2009,58(4):56-57.
[2] Meetoo D,Mc Grovern P,Safadi R. An epidemiological overview of diabetes across the world[J]. Br J Nurs,2007,16(16):1002-1007.
[3] YANG W Y,LU J W,WENG J P,et al.Prevalence of diabetes among men and women in China[J].N Engl J Med,2010,362(12):1090-1100.
[4] Reutens A T,Atkinstkins R C.Epidemiology of diabetic nephropathy[J].Contrib Nephrol,2011,170(1):1-7.
[5] Afkarian M,Sachs M C,Kestenbaum B,et al.Kideny diaease and increased mortality risk in type 2 diabetes[J].J Am Soc Nephrol,2013,24(2):302-308.
[6] 程欣,叶山东,陈燕.2型糖尿病患者抗糖尿病治疗方案与血糖控制关系的研究[J].中国糖尿病杂志,2012,20(7):541-542.
[7] 赵进喜,吕仁和,孟庆刚,等.糖尿病肾病肾功能不全中西医结合防治优化方案多中心临床研究[C]//第四届国际中西医结合肾脏病学术会议专题讲座汇编.天津:中国中西医结合学会肾脏病专业委员会,2006:13-21.
[8] 李景,赵进喜,王世东,等.中医药综合治疗方案全程干预对糖尿病肾病终点事件的影响[J].中医杂志,2012,53(7):568-571,580.
[9] Albefiti K G,Zimmet P Z.Definition,diagnosis and classification of diabetes mellitus provisional report of WHO consultation[J]. Diabetes Med,1998,15(7):539-553.
[10] Mogensen C E,Schmitz A,Christensen C K.Comparative renal pathophysiology relevant to IDDM andNIDDM patients[J].Diabetes Metab Rev,1988,4(5):453-483.
[11] 中国中医药学会糖尿病专业委员会.消渴病中医分期辨证与疗效评定标准——消渴病辨证诊断参考标准[J].中国医药学报,1993,8(3):54-56.
[12] 吕仁和,赵进喜.糖尿病及其并发症中西医诊治学[M].北京:人民卫生出版社,1997:236-243.
[13] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:233-237.
[14] 张舒媛,王东超,李博,等.糖尿病肾病研究进展[J].世界中医药,2015,10(10):1621-1625.
[15] 柳红芳,王皓,胡照娟.2型糖尿病中医体质与肥胖、血脂、血凝指标的相关性分析[J].北京中医药大学学报,2011,34(10):702-706.

相似文献/References:

[1]赵固平,张兴旺,高小玲.尿微量蛋白检测在诊断糖尿病肾病早期损伤中的意义[J].甘肃中医药大学学报,2001,(04):26.
[2]张宏勇,赵继祖.中西医结合治疗早期糖尿病肾病30例临床观察[J].甘肃中医药大学学报,2016,33(05):37.[doi:10.16841/j.issn1003-8450.2016.05.11]
 ZHANG Hongyong,ZHAO Jizu.Clinical observation on 30 cases of early diabetic nephropathy treated with combined therapy of Chinese and Western medicine[J].Journal of Gansu University of Chinese Medicine,2016,33(06):37.[doi:10.16841/j.issn1003-8450.2016.05.11]
[3]马迎儿.加味猪苓汤结合常规疗法治疗糖尿病肾病30例临床观察[J].甘肃中医药大学学报,2017,34(01):42.[doi:10.16841/j.issn1003-8450.2017.01.13]
[4]张玉峰,黄积仓,杨国栋,等.生脉散合归脾汤加减治疗糖尿病肾病Ⅲ期气阴两虚型48例临床观察[J].甘肃中医药大学学报,2012,(06):33.
[5]徐玉娟.海昆肾喜胶囊治疗糖尿病肾病50例疗效观察[J].甘肃中医药大学学报,2012,(06):36.
[6]宋素华,王中甫,孟淑红.伊贝沙坦联合中药治疗糖尿病肾病疗效观察[J].甘肃中医药大学学报,2010,(06):37.
[7]马继国,蒋亚宝.川芎嗪、银杏达莫注射液配合西药治疗糖尿病肾病30例[J].甘肃中医药大学学报,2008,(03):29.
[8]杨小良,张春花.中医药综合治疗对糖尿病肾病患者生存质量的影响[J].甘肃中医药大学学报,2015,32(03):36.
 [J].Journal of Gansu University of Chinese Medicine,2015,32(06):36.
[9]王世彪,周孝德,王向东,等.补肾活血法治疗Ⅲ期糖尿病肾病35例临床观察[J].甘肃中医药大学学报,2002,(03):15.
[10]郭峰,刘锦.刺五加注射液与复方丹参注射液治疗糖尿病肾病微量蛋白尿之疗效对比[J].甘肃中医药大学学报,2002,(04):28.

备注/Memo

备注/Memo:
收稿日期:2017-03-01。
基金项目:江苏省自然科学基金项目(BK20151572)。
作者简介:吴海艳(1979-),女,副主任中医师,医学硕士。研究方向:内分泌代谢性疾病的研究。
通信作者:王旭(1960-),女,主任医师,教授,博士生导师,医学博士。研究方向:内分泌代谢性疾病的研究。E-mail:njzywangxu@126.com
更新日期/Last Update: 1900-01-01